Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Active, not recruiting · NCT04572815 · Registry updated 2026-01-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant | Hemic and Lymphatic Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm | Active, not recruiting | Phase 2 | 2026-01-02 | NCT04572815 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fred Hutchinson Cancer Center | 123 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Comprehensive Cancer Center, | Duarte | United States | 1 |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | United States | 140 |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | United States | 13 |
| Roswell Park Cancer Institute | Buffalo | United States | 382 |